Фармсинтез logo
Фармсинтез LIFE

Фармсинтез Cash Flow 2007-2026 | LIFE

Annual Cash Flow Фармсинтез

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Net Income

-207 M -733 M -527 M -1.81 B 59.8 M -2.84 B -945 M -398 M -199 M -153 M -54.5 M -7.08 M 19.1 M 14 M 2.12 M 16.9 M

Depreciation And Amortization of Intangible Assets

27.5 M 32 M 44.4 M 25.9 M 54.6 M 50.7 M 69.7 M 31.7 M 36.2 M 22.9 M 27.3 M 23.9 M - - - -

Deferred Income Tax

- - - - - - - - - - - - - - - -

Stock Based Compensation

- - - - - - - - - - - - - - - -

Change In Working Capital

95.4 M -11.4 M -23.3 M -49.4 M 319 M 623 M -173 M 193 M -617 M -188 M -95.8 M 44.8 M - - - -

Other Working Capital

95.4 M -798 -102 M -8.74 K - 645 M -199 M 246 M -521 M -161 M -37.7 M 17.7 M - - - -

Other Non Cash Items

81.2 M 650 M 273 M 1.74 B -59.8 M 2.03 B 471 M -30.2 M -61.8 M -34.7 M 6.62 M -8.03 M -19.1 M -14 M -2.12 M -16.9 M

Investments In Property Plant And Equipment

-3.47 M -279 K -9.68 M -14.5 M -19.4 M -24.3 M -33.6 M -14.6 M -81.2 M -125 M -73.2 M -101 M -13.9 M -5 M -3.78 M -

Acquisitions Net

- - - - - -14.8 M -46.5 M -6.83 M -692 K -82 K - -15.1 M - - - -

Purchases Of Investments

- - - - -350 K -53.1 M -64.3 M -6.83 M - -50 M -158 K -118 K - - - -

Sales Maturities Of Investments

- - - - - 54.5 M - - - 72.4 M - - - - - -

Other Investing Activites

-1 M -1.62 M - 37.3 M - 15.8 M 4.16 M 1.2 M -85.1 M 1.36 M -49.4 M -32.6 M -3.49 M -500 K 14 K -

Net Cash Used For Investing Activites

-4.47 M -1.9 M -9.68 M 22.8 M -350 K -21.9 M -75.9 M -20.2 M -167 M -101 M -123 M -148 M -17.4 M -5.5 M -3.77 M -

Debt Repayment

-19 M 69.4 M 94.9 M 144 M -1.5 M - 18.1 M -4.18 M - - -2.71 M -324 K -23.5 M -4.47 M 21.2 M -

Common Stock Repurchased

- - - - - - - - - - - -50 M - - - -

Dividends Paid

- - - - - - - - - - - - - - - -

Other Financing Activites

-6.68 M -1.31 M -3.32 M -3.98 M - 33.5 M -5.77 M -8.61 M -69.6 M -281 M - - -475 M - - -

Net Cash Used Provided By Financing Activities

-1.97 M 68.1 M 179 M 138 M -1.5 M 33.5 M 1.27 B -12.8 M 259 M 889 M -2.71 M -50.3 M 29.5 M -4.47 M 21.2 M -

Effect Of Forex Changes On Cash

3.68 M 1.37 M 7.05 M 150 K 13.6 M 73.9 M -254 M 133 M 355 M 2.08 M - - - - - -

Net Change In Cash

-6.12 M 4.88 M -56.5 M 64.1 M -3.72 M -51.9 M 364 M -104 M -394 M 436 M - - -10.4 M 18.5 M -2.63 M 5.1 M

Cash At End Of Period

9.17 M 15.3 M 10.4 M 64.3 M 233 K 327 M 371 M 7.39 M 111 M 505 M 68.7 M 312 M 11.6 M 22 M 3.49 M 6.12 M

Cash At Beginning Of Period

15.3 M 10.4 M 66.9 M 233 K 3.96 M 379 M 7.39 M 111 M 505 M 68.7 M 312 M 11.6 M 22 M 3.49 M 6.12 M 1.02 M

Operating Cash Flow

-3.35 M -62.7 M -233 M -96.6 M -15.5 M -137 M -577 M -204 M -841 M -353 M -116 M 53.6 M - - - -

Capital Expenditure

-3.47 M -279 K -9.68 M -14.5 M -19.4 M -24.3 M -33.6 M -14.6 M -81.2 M -125 M -72.3 M -82.3 M -13.9 M -5 M -3.78 M -

Free Cash Flow

-6.82 M -63 M -242 M -111 M -34.8 M -162 M -611 M -218 M -922 M -478 M -189 M -28.7 M -13.9 M -5 M -3.78 M -

All numbers in RUB currency

Quarterly Cash Flow Фармсинтез

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q2 2008-Q4

Net Income

-164 K -140 K -67.4 K -445 M -252 M -417 M -108 M -1.77 B -40.5 M -31.5 K -386 K -1.02 M -1.51 M -1.15 M 512 K -71.8 K -283 K -126 K -79.1 K -38.4 M -29.7 M -3.54 M -3.54 M 19.1 M - - - - -

Depreciation And Amortization of Intangible Assets

12.2 K 15.8 K 11.7 K 15.9 M 16 M 26.3 M 18.1 M 419 K 25.5 M 27 K 27.6 K 21.7 K 29 K 34.1 K 37.8 K 15.5 K 16.2 K 24.2 K 12 K 5.98 M 12 M 11.9 M 11.9 M - - - - - -

Deferred Income Tax

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Stock Based Compensation

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Change In Working Capital

-116 K 15.9 K -27.7 K -36.3 M 24.9 M -66.7 M -58.1 M -71.6 M 22.3 M 108 K -21.2 K -105 K 216 K 108 K 6.18 K -78.5 K 152 K -603 K -32.3 K -47 M -94 M 22.4 M 22.4 M - - - - - -

Other Working Capital

- -12.7 K - -399 - -102 M - -4.37 K 7.25 M - - 3.28 K -3.28 K -933 933 907 1.64 K -517 280 -40.2 M -80.3 M 8.83 M 8.83 M - - - - - -

Other Non Cash Items

-77.9 K 128 K 60.4 K 498 M 192 M 334 M 150 M 1.88 B -16.2 M -180 K 344 K 1.11 M 1.11 M 578 K -516 K -23.5 K 69.3 K 252 K -289 K -8.93 M -64.9 M -4.02 M -4.02 M -19.1 M - - - - -

Investments In Property Plant And Equipment

-35 K -1.64 K -1.84 K -211 K -68 K -6.09 M -3.6 M -14.5 M - 4.59 K -23.9 K -6.49 K -2.96 K -9.4 K -1.62 K -13 K -1.65 K -42 K -39.2 K -31.3 M -62.6 M -50.3 M -50.3 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

Acquisitions Net

- - - - - - - - - - - -2.2 K 2.2 K 17.8 K - - - - - - - -7.55 M -7.55 M - - - - - -

Purchases Of Investments

- - - - - - - - - - -175 K -175 K -26.5 M -26.5 M - - - - - -12.5 M -25 M -59 K -59 K - - - - - -

Sales Maturities Of Investments

- - - - - - - - - - - - 27.3 M 27.3 M - - - - - - - - - - - - - - -

Other Investing Activites

154 -1 K - -1.62 M - - - - -24.1 M -28.7 K 28.7 K -12.7 K 289 -83.1 K 507 1.42 K -7.06 K -55.6 K -30.1 K 43.8 M 87.6 M -16.3 M -16.3 M 853 K -4.35 M 8.38 M 16.8 M -8.14 M -4.07 M

Net Cash Used For Investing Activites

-34.9 K -2.64 K -1.84 K -1.84 M -68 K -6.09 M -3.6 M -14.5 M -24.1 M -24.1 K 4.76 K -21.4 K -474 -74.8 K -1.12 K -11.5 K -8.71 K -97.6 K -69.3 K -25.7 M -51.4 M -74.2 M -74.2 M -6.09 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Debt Repayment

- - 5.2 K - - 104 M -8.94 M - - - - - - 1.03 B - - - - - - - -162 K -162 K -23.5 M - - - - -

Common Stock Repurchased

- - - - - - - - - - - - - -3.95 M - - - -8 - - - -25 M -25 M - - - - - -

Dividends Paid

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Other Financing Activites

629 K -7.17 K - 40.1 M 28 M -785 K -27.2 M 98 M 41.6 M 73.3 K 90.6 M 48.8 K -30.5 M -2.45 B 48.1 K -8.91 K -3.89 K -66.5 K 325 K 225 M 450 M - - -464 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Net Cash Used Provided By Financing Activities

629 K -7.17 K 5.2 K 40.1 M 28 M 130 M 49.2 M 98 M 41.6 M 73.3 K 45.3 K 48.8 K -15.3 K 1.22 M 48.1 K -8.91 K -3.89 K -66.5 K 325 K 225 M 450 M -25.2 M -25.2 M 40.8 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Effect Of Forex Changes On Cash

-706 -3.16 K 6.84 K 246 439 5.1 K -1.58 K 3.07 K -58.5 28.3 K -14.6 K 90 K -16.1 K -343 K -88.5 K 174 K -40.9 K 341 K 14.8 K -4.25 M -8.51 M - - - - - - - -

Net Change In Cash

257 K -2.48 K 2.48 K 3.29 M 1.59 M -7.32 M -49.2 M 59.6 M 1.13 M 16 M -985 K -930 K -94.5 M -13 M -1.84 M 90.9 M -27.8 M -26 M -126 M 109 M 218 M - - -10.4 M -2.61 M 4.63 M 4.63 M -657 K -657 K

Cash At End Of Period

124 K - 2.48 K 15.3 M 12 M 10.4 M 17.7 M 66.9 M 1.18 M 16.1 M 4.1 K 58.2 K 193 K 81.7 M 6.58 K 92.8 M 12.3 K 1.85 M 387 K 126 M 252 M 312 M 312 M 11.6 M 2.9 M 5.51 M 5.51 M 874 K 874 K

Cash At Beginning Of Period

- 2.48 K - 12 M 10.4 M 17.7 M 66.9 M 7.32 M 58.2 K 58.2 K 989 K 989 K 94.6 M 94.6 M 1.85 M 1.85 M 27.8 M 27.8 M 126 M 17.2 M 34.4 M 11.6 M 11.6 M 22 M 5.51 M 874 K 874 K 1.53 M 1.53 M

Operating Cash Flow

-346 K 19.7 K -23 K -35.5 M -27.2 M -141 M -91.7 M -23.9 M -45 M -76.9 K -35.8 K 8.9 K -146 K -434 K 40.7 K -158 K -45.4 K -453 K -388 K -88.3 M -177 M 26.8 M 26.8 M - - - - - -

Capital Expenditure

-35 K -1.64 K -1.84 K -211 K -68 K -6.09 M -3.6 M -14.5 M - 4.59 K -23.9 K -6.49 K -2.96 K -9.4 K -1.62 K -13 K -1.65 K -42 K -39.2 K -31.3 M -62.6 M -41.1 M -41.1 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

Free Cash Flow

-381 K 18 K -24.8 K -35.7 M -27.3 M -147 M -95.3 M -38.4 M -45 M -72.3 K -59.8 K 2.42 K -149 K -443 K 39.1 K -171 K -47.1 K -495 K -428 K -120 M -239 M -14.4 M -14.4 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

All numbers in RUB currency

Cash Flow Statement is one of the three key financial reports of the company Фармсинтез, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.54 -20.81 % $ 238 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.79 1.22 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
argenx SE argenx SE
ARGX
$ 748.25 0.25 % $ 25 B niderlandNiderland
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 -4.33 % $ 4.85 M chinaChina
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
AbbVie AbbVie
ABBV
$ 206.69 -1.01 % $ 366 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.39 -3.69 % $ 1.01 B canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 5.97 0.51 % $ 1.44 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.75 0.91 % $ 17.6 B danmarkDanmark
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.23 -0.12 % $ 6.83 B spainSpain
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.32 -4.35 % $ 339 M usaUSA